Research Square (Research Square),
Journal Year:
2023,
Volume and Issue:
unknown
Published: Dec. 19, 2023
Abstract
Purpose:
Endocrine
therapy
(ET)
in
combination
with
CDK
4/6
inhibitors
(CDK
4/6i)
is
the
standard
treatment
modality
for
hormone
receptor
(HR)-positive
and
HER2-negative
metastatic
breast
cancer
(mBC).
For
some
authors,
patients
low
HER2
expression
are
considered
a
different
subgroup.
In
this
study,
we
aimed
to
investigate
prognostic
effect
of
status
on
survival
mBC
treated
first-line
ET
plus
4/6i.
Methods:
This
multicenter
retrospective
study
included
HR+/HER2-negative
who
were
4/6i
from
January
2016
March
2023.
Patients
divided
into
two
groups
(HER2-low
zero),
safety
analyses
performed.
Results:
A
total
201
study;
these,
73
(36.3%)
had
HER2-low
disease
128
(63.7%)
HER2-zero.
There
136
(67.2%)
ribociclib
66
(32.8%)
palbociclib.
Most
(75.1%)
received
aromatase
as
endocrine
therapy.
Baseline
characteristics
similar
between
groups.
The
median
follow-up
was
19.1
months
(range:
2.5–78.4).
most
common
side
neutropenia
(22.4%).
frequency
grade
3–4
toxicity
HER2-zero
(32%
vs.
33.6%;
p
=
0.939).
Visceral
metastases
present
44.8%
patients.
Between
zero
groups,
PFS
(25.2
22.6
months,
0.972)
OS
(not
reached
37.5
0.707)
showed
no
statistically
significant
differences.
Conclusion:
value
remains
controversial.
Our
receiving
ET.
Breast Cancer Research and Treatment,
Journal Year:
2024,
Volume and Issue:
204(3), P. 443 - 452
Published: Jan. 19, 2024
Abstract
Purpose
The
cyclin-dependent
kinase
(CDK)
4/6
inhibitors
significantly
altered
the
treatment
landscape
of
hormone-positive
(HR+),
HER2-
metastatic
breast
cancer
(MBC).
However,
biomarkers
predicting
long-term
benefit
and
early
progression
are
yet
to
be
defined.
Several
studies
suggested
possibility
diminished
efficacy
in
patients
with
HER2-low
disease.
Therefore,
we
conducted
a
systematic
review
meta-analysis
evaluate
association
between
low-level
HER2
expression
outcomes
(PFS,
OS,
ORR)
CDK
inhibitors.
Methods
Pubmed,
Web
Science,
Scopus
databases
were
used
systematically
filter
published
from
inception
08
August
2023
for
this
systemic
review.
Studies
including
MBC
treated
reported
survival
according
included.
We
performed
meta-analyses
generic
inverse-variance
method
fixed-effects
model
HRs
95%
two-sided
CIs
as
principal
summary
measure.
Results
Nine
encompassing
2705
included
analyses.
In
pooled
analysis
nine
studies,
risk
and/or
death
was
higher
tumors
compared
HER2-zero
(HR:
1.22,
CI
1.10–1.35,
p
<
0.001).
five
although
median
follow-up
short,
group
1.04–1.44,
=
0.010).
Conclusion
available
evidence
demonstrates
or
tumors.
Further
research
is
needed
improve
HR+-HER2-low
Frontiers in Oncology,
Journal Year:
2024,
Volume and Issue:
14
Published: Aug. 29, 2024
Background
The
combination
of
CDK4/6
inhibitors
(CDK4/6i)
and
endocrine
therapy
(ET)
is
currently
the
standard
first-line
treatment
for
patients
with
metastatic
hormone
receptor
positive
(HR+),
HER2-negative
(HER2-)
breast
cancer.
However,
impact
HER2
status
on
prognosis
receiving
CDK4/6i
ET
remains
unclear.
meta-analysis
was
conducted
to
evaluate
different
outcomes
between
HER2-low
HER2-zero
in
advanced
HR+
cancer
ET.
Methods
A
systematic
search
performed
PubMed
EMBASE
databases
relevant
published
literature.
Objective
response
rate
(ORR),
overall
survival
(OS),
progression-free
(PFS)
were
pooled
by
fixed
or
random
effects
models.
Results
Overall,
12
studies
3567
eligible
analysis.
analysis
suggested
that
no
significant
differences
observed
terms
ORR
OS
who
underwent
Similarly,
difference
PFS
found
post-line
Palbociclib
received
mixed-line
(not
a
single
line)
ET,
significantly
shorter
subgroup
than
(mixed-line:
HR
=
1.36;
95%
CI
1.11–1.65;
P
0.002;
first-line:
1.14;
1.01–1.28;
0.04).
similar
phenomenon
1.60;
1.09–2.34;
0.02;
post-line:
1.43;
1.03–2.00;
0.03).
Conclusion
These
results
indicated
did
not
have
association
OS,
but
it
may
worse
as
well
palbociclib
plus
Breast Cancer Research and Treatment,
Journal Year:
2024,
Volume and Issue:
205(3), P. 633 - 640
Published: March 25, 2024
Abstract
Purpose
Endocrine
therapy
(ET)
in
combination
with
CDK
4/6
inhibitors
(CDK
4/6i)
is
the
standard
treatment
modality
for
hormone
receptor
(HR)-positive
and
HER2-negative
metastatic
breast
cancer
(mBC).
There
uncertainty
about
prognostic
predictive
value
of
HER2-low
status
whether
BC
an
individual
biologic
subtype.
In
this
study,
we
aimed
to
investigate
effect
HER2
expression
on
survival
mBC
patients
treated
first-line
ET
plus
4/6i.
Methods
This
multicenter
retrospective
study
included
HR
+
/HER2-negative
who
were
4/6i
from
January
2016
March
2023.
Patients
divided
into
two
groups
(HER2-low
zero),
safety
analyses
performed.
Results
A
total
201
study;
these,
73
(36.3%)
had
disease
128
(63.7%)
HER2-zero.
135
(67.2%)
ribociclib
66
(32.8%)
palbociclib.
Most
(75.1%)
received
aromatase
as
combination-endocrine
therapy.
Baseline
characteristics
similar
between
groups.
The
median
follow-up
was
19.1
months
(range:
2.5–78.4).
most
common
side
neutropenia
(22.4%).
frequency
grade
3–4
toxicity
HER2-zero
low
(32%
vs
31.5%;
p
=
0.939).
Visceral
metastases
present
44.8%
patients.
Between
zero
groups,
PFS
(25.2
22.6
months,
0.972)
OS
(not
reached
37.5
0.707)
showed
no
statistically
significant
differences.
Conclusion
remains
controversial.
Our
receiving
ET.
Current Oncology,
Journal Year:
2024,
Volume and Issue:
31(12), P. 7426 - 7436
Published: Nov. 22, 2024
Background/Objectives:
Dose
reductions
in
CDK4/6
inhibitors,
such
as
ribociclib
and
palbociclib,
are
often
necessary
due
to
treatment-related
toxicities
patients
with
advanced
breast
cancer.
This
study
aims
evaluate
the
impact
of
timing
dose
on
progression-free
survival
(PFS)
overall
(OS)
a
real-world
cohort.
Methods:
single-center,
retrospective
included
treated
or
palbociclib
between
2019
2023
at
cancer
center
Turkey.
drug-related
were
recorded,
outcomes
analyzed.
Patients
categorized
based
reductions:
within
first
3
months
(early)
after
(late).
Results:
Among
392
(mean
age
57.13
years),
16.8%
had
months,
21.7%
late
reductions,
61.5%
no
reductions.
The
mPFS
was
14.26
for
early
33.12
20.6
(p
<
0.001).
mOS
37.12
not
reached
57.76
Hematological
toxicity,
primarily
neutropenia,
most
common
cause
ECOG
performance
status,
line
therapy,
inhibitor
type
also
significant
predictors
PFS
OS.
Conclusions:
Early
inhibitors
negatively
affect
OS,
highlighting
importance
maintaining
treatment
intensity
months.
However,
do
(OS),
associated
better
outcomes.
Prospective
studies
larger
patient
populations
will
further
clarify
our
knowledge
this
subject.
Medicine,
Journal Year:
2024,
Volume and Issue:
103(52), P. e41082 - e41082
Published: Dec. 27, 2024
For
patients
with
human
epidermal
growth
factor
receptor
2
(HER2)-low
advanced
breast
cancer
who
had
failed
to
meet
anthracycline
or
taxane,
the
application
of
HER2-targeted
antibody-drug
conjugates
as
second-line
therapy
could
improve
patients'
outcomes,
but
it
is
unclear
whether
carboplatin-based
first-line
will
benefit
these
patients.
This
retrospective
study
was
designed
explore
carboplatin
based
treatment
outcomes
in
HER2-low
cancer,
and
analyze
potential
factors
affecting
efficacy
prognosis.
103
HER2-negative
metastatic
were
treated
therapy.
The
differences
progression-free
survival
(PFS),
objective
response
rate
(ORR),
adverse
events
analyzed
different
HER2
expression
subgroups.
risk
ratio
(HR)
95%
confidence
interval
(CI)
for
PFS
estimated
using
Cox
proportional
models.
ORR
whole
group
42.72%
median
(mPFS)
7.93
months
(m).
significantly
higher
than
HER2-zero
(56.4%
vs
27.1%,
P
=
.003),
an
independent
(OR
3.478,
95%CI
1.516-7.977,
especially
HR-negative
subgroup.
mPFS
longer
low
neutrophil-to-lymphocyte
(NLR)
scores
those
high
NLR
(P
<
.001).
Multivariate
analysis
showed
that
young
(age
40)
.006)
values
.001)
prognostic
mPFS.
main
grade
3
4
reactions
neutropenia
(15.53%),
anemia
leukopenia
(11.65%).
chemotherapy
quite
active
tolerable
rates
can
be
achieved.
In
cases
where
CDK4/6
inhibitors
are
inappropriate
use
due
resistance
endocrine
urgent
need
short-term
clinical
response,
remains
important.
When
necessary
consider
accessibility
economics
patients,
may
provided
a
more
convenient,
cost-effective
efficient
option
on
front
line.
Forecasting
prognosis
via
inflammatory
index
such
before
commencement
enhance
precision
efficiency
regimens.
Medicine,
Journal Year:
2024,
Volume and Issue:
103(30), P. e38828 - e38828
Published: July 26, 2024
The
fact
that
the
human
epidermal
growth
factor
receptor
2
(HER2)-low
group,
historically
classified
as
HER2
negative
in
breast
cancer
histology,
benefited
from
HER2-targeted
treatments
similarly
to
HER2-positive
group
indicates
this
has
a
distinct
histology
HER2-0
group.
effectiveness
of
cyclin-dependent
kinase
4/6
inhibitors,
which
are
standard
first-line
treatment
for
hormone
receptor-positive,
HER2-negative
advanced
cancer,
newly
defined
histological
subgroup
remains
topic
debate.
In
our
study,
we
examined
impact
status
on
efficacy
CDK4/6
inhibitors.
Our
study
is
retrospective,
multicenter,
real-world
data
analysis.
One
hundred
sixty
patients
were
included
study.
relationship
between
and
other
clinical-pathological
features,
well
progression-free
survival,
was
examined.
Median
follow-up
20.33
±
0.98
months.
mPFS
could
not
be
reached.
All
exhibited
positive
estrogen
expression.
Among
patients,
111
(69.4%)
categorized
HER2-0,
49
(30.6%)
HER2-low.
24-month
survival
rates
similar
HER2-low
(60.6%
vs
65.3%,
receptor:
1.18,
CI:
0.67-2.20,
P
=
.554).
We
established
achieved
with
inhibitors
therapy
unaffected
by
status.
